drugset / Trial / NCT04740814

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

NCT04740814

Phase 1 Completed 33 enrolled UCB Biopharma SRL
NaSingle-groupOpen-labelBasic science

Summary

The purpose of the study is to evaluate the pharmacokinetics and safety of certolizumab pegol in adults with active rheumatoid arthritis.

Timeline

Start
2021-02-11
Primary completion
2022-01-24
Completion
2022-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Certolizumab Pegol Protein / enzyme biologic Subcutaneous

Indications